ONC.TO - Oncolytics Biotech Inc.

Toronto - Toronto Delayed Price. Currency in CAD

Oncolytics Biotech Inc.

210, 1167 Kensington Crescent NW
Calgary, AB T2N 1X7

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Matthew C. CoffeyPres, CEO & Director568.07kN/AN/A
Mr. Kirk J. Look CAChief Financial Officer459.96kN/AN/A
Dr. Andres A. Gutierrez M.D., Ph.D.Chief Medical Officer75.04kN/A1961
Mr. Michael MooreVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Andrew R. de GuttadauroGlobal Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) IncN/AN/A1967
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Corporate Governance

Oncolytics Biotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.